- Cerebrolysin 10 x 2 ml- Cerebrolysin 5 x 5 ml- Cerebrolysin 5 x 10 ml Cerebrolysin is a neurometabolic stimulator based on neuropeptides (20 percent) and amino acids (80 percent) isolated from pig brain tissue.
It was developed in 1949 by Gerhart Harrer, an Austrian professor, and approved on August 1, 1954.
Used as a treatment for: - Strokes and complications associated with strokes- Depression, anxiety, and other brain diseases- Alzheimer's disease and other types of dementia- Traumatic brain injury and spinal cord injuries- ADHD in children Country of Manufacture: Austria Contraindications– individual intolerance to the drug– acute renal failure– status epilepticus Side effects– fever, sensation of heat (with rapid intravenous infusion)Rarely:– headache, dizziness– loss of appetite, nausea, vomiting, dyspepsia, diarrhea, constipation– allergic reactions: skin redness, itching and burning at the injection site Mode of applicationIt is used only parenterally: in the form of intramuscular injections (up to 5 ml), and intravenous infusions (10-60 ml), it is recommended to enter only by slow intravenous infusions after dilution with the proposed standard solutions for infusion.
Doses and duration of treatment depend on the nature and severity of the disease, as well as on the patient’s age.
The standard duration of treatment is 4 weeks (5 injections / infusions per week, preferably daily).To increase the effectiveness of treatment, repeated courses can be carried out until positive treatment results are obtained.
After the first course, the frequency of prescribing doses can be reduced to 2 or 3 times a week.In Alzheimer’s disease, dementia syndrome of various origins: intravenous infusion of 20-30 ml in 100-200 ml of saline, for a course of treatment 20 infusions, 5 infusions per week (followed by a 2-day break) for 28 days.